Login to Your Account

Financings Roundup

Chelsea Therapeutics Extends Cash Runway, Raises $35M

By Catherine Shaffer

Tuesday, February 22, 2011
After extending and restructuring its Phase III trial of Northera (droxidopa) for neurogenic orthostatic hypotension (NOH) in Parkinson's patients, Chelsea Therapeutics Inc. needed a bit more of a cash boost to carry it through to launch.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription